Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ashique Rafique

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Journal of Lipid Research|May 13, 2015
ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeysViktoria Gusarova, Corey A Alexa, Yan Wang, et al.
Cancer Research|July 31, 2024
A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic VariantsYan Yang, Avvaru N Suhasini, Zaoli Jiang, et al.
Nature Communications|April 29, 2017
Activin A more prominently regulates muscle mass in primates than does GDF8Esther Latres, Jason Mastaitis, Wen Fury, et al.
Molecular Cancer Therapeutics|August 10, 2019
Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human <i>PD-1xLAG-3</i>-Knockin MiceElena Burova, Aynur Hermann, Jie Dai, et al.
Molecular Cancer Therapeutics|March 18, 2014
ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer modelsLi Zhang, Carla Castanaro, Bo Luan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2019
A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor ModelsJohn O DaSilva, Katie Yang, Andres E Perez Bay, et al.
Allergy|December 16, 2019
Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammationAudrey Le Floc'h, Jeanne Allinne, Kirsten Nagashima, et al.
Angiogenesis|May 29, 2016
Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexesDouglas A MacDonald, Joel Martin, Kathir K Muthusamy, et al.
Nature Structural Biology|December 7, 2002
Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclusteringSamuel Davis, Nick Papadopoulos, Thomas H Aldrich, et al.
Elife|June 10, 2020
Activin A forms a non-signaling complex with ACVR1 and type II Activin/BMP receptors via its finger 2 tip loopSenem Aykul, Richard A Corpina, Erich J Goebel, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Journal of Lipid Research|May 13, 2015
ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeysViktoria Gusarova, Corey A Alexa, Yan Wang, et al.
Cancer Research|July 31, 2024
A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic VariantsYan Yang, Avvaru N Suhasini, Zaoli Jiang, et al.
Nature Communications|April 29, 2017
Activin A more prominently regulates muscle mass in primates than does GDF8Esther Latres, Jason Mastaitis, Wen Fury, et al.
Molecular Cancer Therapeutics|August 10, 2019
Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human <i>PD-1xLAG-3</i>-Knockin MiceElena Burova, Aynur Hermann, Jie Dai, et al.
Molecular Cancer Therapeutics|March 18, 2014
ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer modelsLi Zhang, Carla Castanaro, Bo Luan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2019
A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor ModelsJohn O DaSilva, Katie Yang, Andres E Perez Bay, et al.
Allergy|December 16, 2019
Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammationAudrey Le Floc'h, Jeanne Allinne, Kirsten Nagashima, et al.
Angiogenesis|May 29, 2016
Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexesDouglas A MacDonald, Joel Martin, Kathir K Muthusamy, et al.
Nature Structural Biology|December 7, 2002
Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclusteringSamuel Davis, Nick Papadopoulos, Thomas H Aldrich, et al.
Elife|June 10, 2020
Activin A forms a non-signaling complex with ACVR1 and type II Activin/BMP receptors via its finger 2 tip loopSenem Aykul, Richard A Corpina, Erich J Goebel, et al.
Pageof 5